文献速递肝病

肝外癌症是病毒性肝硬化患者实现乙肝病毒控制或丙肝病毒清除后的首位死因

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
PubMed 文献 · Hepatology · 2018-07-10

法国35中心前瞻性CO12 CirVir队列纳入1671例活检证实的代偿期病毒性肝硬化患者(HCV 1323例、HBV 317例、HCV-HBV 31例),中位随访59.7个月。与法国一般人群相比,HCV肝硬化患者肝外癌症风险升高(SMR 1.31,95%CI 1.04-1.64,P=0.017),获得持续病毒应答者亦升高(SMR 1.57,95%CI 1.08-2.22,P=0.013);肝外癌症为全队列第四位死因,在病毒控制/清除者中为第一位死因。

要点

  • HCV肝硬化患者肝外癌症风险高于法国一般人群(SMR 1.31,95%CI 1.04-1.64,P=0.017)。
  • HCV患者获得持续病毒应答后肝外癌症风险仍升高(SMR 1.57,95%CI 1.08-2.22,P=0.013)。
  • 肝外癌症在病毒控制/清除的肝硬化患者中为第一位死因,全队列中为第四位死因。

核心结论

  • 与法国一般人群相比,HCV肝硬化与更高的肝外癌症风险相关,且肝外癌症是病毒性肝硬化患者实现病毒学控制/清除后的第一位死因。

研究设计与样本

  • 法国35个中心的前瞻性多中心ANRS CO12 CirVir队列,2006年至2012年纳入1671例活检证实的代偿期病毒性肝硬化患者(HCV 1323例、HBV 317例、HCV-HBV 31例)。
  • 纳入标准为活检证实的HBV或HCV肝硬化、Child-Pugh A级、无既往肝脏并发症包括原发性肝癌。
  • 患者每6个月前瞻性随访,按年龄和性别以5年分段计算标准化死亡比(SMR),HCV患者的持续病毒应答和HBV患者的持续病毒抑制采用时间依赖分析评估。

主要发现

  • 中位随访59.7个月,诊断227例原发性肝癌(5年累积发生率13.4%),93例发生肝外癌症(14例淋巴或相关组织癌症、79例实体组织癌症;5年肝外癌症累积发生率5.9%)。
  • 与法国一般人群相比,患者癌症诊断时更年轻,HCV患者肝外癌症风险显著升高(SMR 1.31,95%CI 1.04-1.64,P=0.017),获得持续病毒应答后亦升高(SMR 1.57,95%CI 1.08-2.22,P=0.013)。
  • 肝外癌症为全队列第四位死因,在病毒控制/清除患者中为第一位死因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Data on extrahepatic cancers (EHCs) in compensated viral cirrhosis are limited. The objective of the prospective multicenter Agence Nationale de Recherche sur le SIDA et les Hépatites virales CO12 CirVir cohort was to assess the occurrence of all clinical events in patients with compensated viral cirrhosis, including all types of cancer. Patients with the following inclusion criteria were enrolled in 35 French centers: (1) biopsy-proven hepatitis B virus (HBV) or hepatitis C virus (HCV) cirrhosis, (2) Child-Pugh A, or (3) absence of previous liver complications including primary liver cancer (PLC). Patients were followed up prospectively every 6 months. The standardized mortality ratio (SMR) was calculated according to age and gender using 5-year periods. The impact of sustained viral response (SVR) in HCV patients and maintained viral suppression in HBV patients were assessed using time-dependent analysis. A total of 1,671 patients were enrolled between 2006 and 2012 (median age, 54.9 years; men, 67.3%; HCV, 1,323; HBV, 317; HCV-HBV, 31). Metabolic features and excessive alcohol and tobacco consumption were recorded in 15.2%, 36.4%, and 56.4% of cases, respectively. After a median follow-up of 59.7 months, 227 PLCs were diagnosed (5-year cumulative incidence [CumI] 13.4%) and 93 patients developed EHC (14 patients with lymphoid or related tissue cancer and 79 with solid tissue cancer; 5-year EHC CumI, 5.9%). Compared to the general French population, patients were younger at cancer diagnosis, with significantly higher risk of EHC in HCV patients (SMR, 1.31; 95 confidence interval [CI], 1.04-1.64; P = 0.017) and after SVR (SMR = 1.57; 95% CI, 1.08-2.22; P = 0.013). EHC was the fourth leading cause of death in the whole cohort and the first in patients with viral control/eradication. CONCLUSION: Compared to the general French population, HCV cirrhosis is associated with a higher risk of EHC and the first cause of death in patients with viral cirrhosis who achieve virological control/eradication. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Allaire M, Nahon P, Layese R, et al. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology. 2018. PMID: 29663511. doi:10.1002/hep.30034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。